Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Monensin Inhibits Triple-Negative Breast Cancer in Mice by a Na + -Dependent Cytotoxic Action Unrelated to Cytostatic Effects.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI
    • الموضوع:
      Monensin*/pharmacology ; Monensin*/therapeutic use ; Triple Negative Breast Neoplasms*/drug therapy ; Triple Negative Breast Neoplasms*/pathology ; Triple Negative Breast Neoplasms*/metabolism ; Sodium*/metabolism ; Cytostatic Agents*/pharmacology; Animals ; Female ; Mice ; Mice, Inbred BALB C ; Cell Line, Tumor ; Humans ; Cell Proliferation/drug effects
    • نبذة مختصرة :
      Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype, defined by its limited therapeutic options and poor outcomes. This study investigated the therapeutic potential of targeting Na + homeostasis in TNBC cells to induce TNBC inhibition. For this purpose, BALB/c mice were inoculated with 4T1-Luc2 breast cancer cells and treated with the Na + ionophore monensin (8 mg/kg) or vehicle alone. Tumor development and cellular Na + content were assessed using vivo live imaging techniques, while intracellular Na + variations and cytotoxicity were evaluated through live cell analysis. Monensin treatment increased Na + levels in cancerous tissues and reduced TNBC mass (monensin: 0.146 ± 0.06; vehicle: 0.468 ± 0.2 cm 3 ; p < 0.001). This treatment induced extensive necrosis in TNBC tumors while preserving the structural and functional integrity of healthy organs and maintaining the proliferative activity of both tumor and normal tissues. Monensin did not alter the expression of proliferating nuclear antigen (PCNA) in 4T1-Luc2 cells but triggered cytotoxicity preceded by intracellular Na + accumulation. Na + -free conditions prevented both Na + accumulation and 4T1-Luc2 cell death. Thus, monensin exerts its antitumor effects in TNBC through a Na + -dependent and tumor-specific cytotoxic mechanism, without inducing cytostatic effects on normal or transformed tissues. Collectively, these findings underscore the potential of Na + ionophores as promising therapeutic agents for TNBC.
    • References:
      Nat Rev Cancer. 2011 Aug 11;11(9):671-7. (PMID: 21833026)
      Nat Rev Cancer. 2004 Nov;4(11):891-9. (PMID: 15516961)
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      J Neuroimaging. 2021 Mar;31(2):297-305. (PMID: 33351997)
      Front Oncol. 2021 Dec 03;11:778823. (PMID: 34926288)
      Lancet. 2021 May 8;397(10286):1750-1769. (PMID: 33812473)
      Breast Cancer Res Treat. 2012 Dec;136(3):795-804. (PMID: 23124476)
      J Pain Symptom Manage. 2017 Aug;54(2):245-258.e2. (PMID: 28533160)
      ALTEX. 2018;35(1):99-118. (PMID: 28800376)
      Chirality. 2002 Feb-Mar;14(2-3):121-5. (PMID: 11835554)
      J Anim Sci. 1984 Jun;58(6):1512-7. (PMID: 6746442)
      Hepatology. 1995 Apr;21(4):1089-98. (PMID: 7705784)
      Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. (PMID: 34754128)
      PeerJ. 2019 Jul 25;7:e7354. (PMID: 31380151)
      Magn Reson Imaging. 2012 Nov;30(9):1268-78. (PMID: 22819581)
      J Nanobiotechnology. 2022 Oct 15;20(1):450. (PMID: 36243718)
      Drug Dev Res. 2020 Sep;81(6):745-753. (PMID: 32462716)
      Curr Opin Obstet Gynecol. 2006 Feb;18(1):24-8. (PMID: 16493256)
      J Pers Med. 2021 Jun 05;11(6):. (PMID: 34198738)
      Exp Ther Med. 2021 Dec;22(6):1390. (PMID: 34650638)
      Prog Nucl Magn Reson Spectrosc. 2023 Nov-Dec;138-139:1-51. (PMID: 38065665)
      Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
      Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. (PMID: 27184417)
      Sci Rep. 2015 Dec 07;5:17523. (PMID: 26639992)
      Cancer Immunol Res. 2014 Apr;2(4):361-70. (PMID: 24764583)
      Radiology. 2021 Apr;299(1):63-72. (PMID: 33591888)
      Angew Chem Int Ed Engl. 2018 Jun 18;57(25):7468-7472. (PMID: 29575414)
      Commun Biol. 2023 May 29;6(1):574. (PMID: 37248274)
      Gastroenterology. 2003 Nov;125(5):1480-91. (PMID: 14598265)
      J Med Toxicol. 2017 Sep;13(3):259-262. (PMID: 28516409)
      Invest Radiol. 2018 Aug;53(8):450-456. (PMID: 29969108)
      Exp Cell Res. 1999 Apr 10;248(1):280-93. (PMID: 10094834)
      Am J Kidney Dis. 2001 Nov;38(5):1108-12. (PMID: 11684567)
      Cancers (Basel). 2022 Sep 21;14(19):. (PMID: 36230495)
      Bioorg Med Chem Lett. 2019 Jul 1;29(13):1549-1554. (PMID: 31054863)
      Br J Cancer. 2022 Jul;127(2):337-349. (PMID: 35462561)
    • Grant Information:
      IG-2020-24351 Italian Association for Cancer Research
    • Contributed Indexing:
      Keywords: Na+ ionophores; anticancer treatment; cancer cell death
    • الرقم المعرف:
      906O0YJ6ZP (Monensin)
      9NEZ333N27 (Sodium)
      0 (Cytostatic Agents)
    • الموضوع:
      Date Created: 20250212 Date Completed: 20250212 Latest Revision: 20250519
    • الموضوع:
      20250520
    • الرقم المعرف:
      PMC11817484
    • الرقم المعرف:
      10.3390/cells14030185
    • الرقم المعرف:
      39936977